(CDTX) - Earnings & Price History

CDTX: - 7.35, $129.24M, -0.35 (-4.55%)

Sector: Healthcare - Industry: Biotechnology

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patients immune cells to attack and eliminate pathogens that cause infectious disease, as well as engages in evaluating Cloudbreak candidates for the treatment of invasive fungal infections, including aspergillosis, an infection caused by the fungal patho

Past CDTX reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2016-08-11-0.7611.8712.1311.7611.6512.04-3.05%0.94%-2.14%31.24K
2016-08-10-0.7612.1311.5711.5111.512.16-0.52%5.39%4.84%42.74K
2016-08-09-0.7611.5712.1512.0311.4612.14-0.99%-3.82%-4.77%38.33K
2016-03-18-0.7

Login | Register
Saturday Nov 17, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades